Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.

@article{Ford2008PharmacokineticIB,
  title={Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.},
  author={Susan L. Ford and Y Chen and Yu F Lou and Julie Borland and Sherene S. Min and Geoffrey J. Yuen and Mark J Shelton},
  journal={Antimicrobial agents and chemotherapy},
  year={2008},
  volume={52 2},
  pages={534-8}
}
Rifabutin (RFB) is administered for treatment of tuberculosis and Mycobacterium avium complex infection, including use for patients coinfected with human immunodeficiency virus (HIV). Increased systemic exposure to RFB and its equipotent active metabolite, 25-O-desacetyl-RFB (dAc-RFB), has been reported during concomitant administration of CYP3A4 inhibitors, including ritonavir (RTV), lopinavir, and amprenavir (APV); therefore, a reduction in the RFB dosage is recommended when it is… CONTINUE READING
8 Citations
9 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-9 of 9 references

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin

  • A. Cato, III, +4 authors R. Granneman
  • Clin. Pharmacol. Ther
  • 1998

Similar Papers

Loading similar papers…